Navigation Links
Bioheart, Inc. Announces Financial Results for First Quarter 2008
Date:5/15/2008

SUNRISE, Fla., May 15 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today announced financial results for the quarter ended March 31, 2008.

Financial Highlights

-- On February 19, 2008, the Company completed its initial public offering

(IPO) of common stock for gross proceeds of approximately $5.8 million.

The net cash proceeds from the IPO are expected to be utilized to

commence full-scale enrollment in a Phase II/III MARVEL Clinical Trial

of MyoCell(R) in the U.S. and Europe.

Clinical Highlights

-- On January 18, 2008, the final 12-month results of the MYOHEART Trial,

a Phase I dose-escalation study of MyoCell in the United States, the

Company's lead product candidate, were presented at the Fourth Annual

International Conference on Cell Therapy for Cardiovascular Diseases

(NY). The results, presented by Warren Sherman, MD, Principal

Investigator and Director, Cell-based Endovascular Therapies, Columbia

University Medical Center, NY, suggested trends in improved quality of

life measurements sustained out to 12 months following treatment,

without unexpected rates of serious adverse events related to the

therapy given its patient population.

-- On April 1, 2008, the final six-month results of the Phase II SEISMIC

Trial of MyoCell in Europe, was presented during the clinical trial

sessions at the American College of Cardiology. These results suggested

that MyoCell is a safe and potentially effective alternative treatment

to standard medical therapy alone for improving heart function among

patients with previously implanted cardiac devices who are experiencing

congestive hea
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
(Date:7/10/2014)... will see the two universities and NPL collaborate to ... and industry and their complementary academic strengths., Working with ... shape the scientific priorities of the UK. The establishment ... 300 high-calibre PhD students, will provide a pipeline of ... potential of the Laboratory will be grown through the ...
(Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a group ... is teaming up with the Heartland Blood Center and offering ... drive. The drive takes place Saturday, Jan. 18 at the ... 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
Breaking Biology Technology:New strategy could uncover genes at the root of psychiatric illnesses 2Even geckos can lose their grip 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3Join the Bill Jacobs Auto blood drive and receive a free oil change 2
... HOPKINTON, Mass. , May 18 Caliper Life Sciences, Inc. ... drug discovery and life sciences research, today announced that it reached an ... ® evaporation product lines to Biotage AB for $16.5 million ... , ...
... Sigma-Aldrich Corporation (Nasdaq: SIAL ) will be presenting at the Baird,s ... PM CDT ( 2:15 PM EDT ) in Chicago, IL. ... http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to access this file. ... About Sigma-Aldrich: ...
... , May 17 Three years of teamwork between ... Gunma University Heavy Ion Medical Center used carbon ion radiotherapy to treat ... the use of Elekta,s treatment planning software, XiO® , for delivery ... , , ...
Cached Biology Technology:Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 2Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 3Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 4Sigma-Aldrich Corporation to Present at the Baird's 2010 Growth Stock Conference on Thursday, May 20, 2010 2Elekta / Mitsubishi Electric Collaboration Helps Japan's Gunma University Heavy Ion Medical Center Launch Advanced Carbon Ion Therapy for Treating Cancer 2
(Date:7/10/2014)... and other major cities in New Mexico, nearly every ... wastewater rather than precious potable water supplies. Across the ... all golf courses receive treated effluent. Reusing the effluent ... golf courses and homeowners alike fertilize their lawns during ... nitrate. A New Mexico State University turfgrass expert has ...
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... and services, previously announced on June 26, 2014 that ... dividend of $1.75 per share, or approximately $40 million ... July 10, 2014 and a payment date of July ... that it had set an ex-dividend date for this ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... have used a genetically reprogrammed herpes virus and an ... model metastatic disease in mice still an elusive ... study in the July 8 Gene Therapy . ... cancer survive beyond five years, despite the aggressive use ...
... in a fraction of the blink of an eye, but ... And there has been no guarantee of success, even with ... researchers have come up with a computer program to accurately ... allow scientists to peer deeper into the roots of diseases ...
... York University study has shown for the first time ... neurodevelopmental defects associated with autism, interferes with neuronal cell ... is similar in structure to naturally-occurring prostaglandins, which are ... the brain. Past clinical studies have shown an ...
Cached Biology News:Genetically reprogrammed HSV given systemically shrinks distant sarcomas 2Rice program takes on protein puzzle 2Rice program takes on protein puzzle 3York U autism-related study discovers how drug interferes with neuronal cell function 2
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Plasmid expressing PLAP reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
Biology Products: